Barclays Increases Eli Lilly And Co (LLY) Price Target to $120.00

Eli Lilly And Co (NYSE:LLY) had its price target raised by Barclays from $112.00 to $120.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The brokerage currently has an “overweight” rating on the stock. Barclays’ target price points to a potential upside of 8.62% from the company’s previous close.

A number of other analysts have also recently weighed in on LLY. Credit Suisse Group raised their price objective on Eli Lilly And Co from $82.00 to $84.00 and gave the stock an “underperform” rating in a research report on Thursday, June 21st. DZ Bank reaffirmed a “hold” rating on shares of Eli Lilly And Co in a research report on Friday, June 22nd. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b” rating in a research report on Friday, June 29th. Cantor Fitzgerald set a $100.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, July 9th. Finally, Jefferies Financial Group set a $100.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Sunday, July 15th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $108.38.

Eli Lilly And Co stock opened at $110.48 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $115.25 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The firm had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.11 EPS. As a group, equities research analysts expect that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $115.91, for a total transaction of $1,695,995.12. Following the completion of the transaction, the insider now owns 119,191,172 shares in the company, valued at approximately $13,815,448,746.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total value of $637,860.00. Following the transaction, the senior vice president now owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,785,575 shares of company stock valued at $180,166,130. 0.11% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avestar Capital LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at about $100,000. First Command Financial Services Inc. increased its stake in shares of Eli Lilly And Co by 7.3% in the 1st quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after purchasing an additional 84 shares in the last quarter. Gradient Investments LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at about $103,000. Integrated Wealth Concepts LLC purchased a new position in shares of Eli Lilly And Co in the 2nd quarter valued at about $103,000. Finally, Iowa State Bank purchased a new position in shares of Eli Lilly And Co in the 2nd quarter valued at about $104,000. Institutional investors and hedge funds own 76.56% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How to Invest in Marijuana Stocks

Stock Target Advisor

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply